Insider Selling: Global Blood Therapeutics Inc (GBT) Insider Sells 3,000 Shares of Stock

Global Blood Therapeutics Inc (NASDAQ:GBT) insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $52.85, for a total value of $158,550.00. Following the transaction, the insider now directly owns 137,255 shares in the company, valued at approximately $7,253,926.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jung Choi also recently made the following trade(s):

  • On Monday, December 18th, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The stock was sold at an average price of $36.55, for a total value of $109,650.00.

Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) traded up $2.80 during midday trading on Monday, reaching $59.95. The company’s stock had a trading volume of 481,730 shares, compared to its average volume of 1,190,000. The company has a market cap of $2,760.00 and a price-to-earnings ratio of -23.51. Global Blood Therapeutics Inc has a fifty-two week low of $18.95 and a fifty-two week high of $65.40.

GBT has been the topic of several research analyst reports. Wedbush reissued an “outperform” rating and issued a $73.00 price objective on shares of Global Blood Therapeutics in a research report on Monday, December 4th. BidaskClub raised Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. HC Wainwright set a $73.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday, December 11th. Oppenheimer set a $53.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday, November 13th. Finally, Nomura upped their price target on Global Blood Therapeutics to $91.00 and gave the company a “buy” rating in a research report on Monday, December 11th. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $63.27.

A number of hedge funds and other institutional investors have recently made changes to their positions in GBT. Schwab Charles Investment Management Inc. boosted its holdings in shares of Global Blood Therapeutics by 35.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 149,634 shares of the company’s stock worth $4,093,000 after purchasing an additional 38,829 shares in the last quarter. Rhumbline Advisers boosted its holdings in Global Blood Therapeutics by 118.5% during the 2nd quarter. Rhumbline Advisers now owns 41,801 shares of the company’s stock valued at $1,143,000 after acquiring an additional 22,670 shares during the period. Bank of New York Mellon Corp boosted its holdings in Global Blood Therapeutics by 32.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 184,173 shares of the company’s stock valued at $5,037,000 after acquiring an additional 44,784 shares during the period. Legal & General Group Plc boosted its holdings in Global Blood Therapeutics by 93.4% during the 2nd quarter. Legal & General Group Plc now owns 9,315 shares of the company’s stock valued at $256,000 after acquiring an additional 4,499 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its holdings in Global Blood Therapeutics by 694.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after acquiring an additional 3,975 shares during the period. Institutional investors and hedge funds own 85.95% of the company’s stock.

WARNING: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/12/insider-selling-global-blood-therapeutics-inc-gbt-insider-sells-158550-00-in-stock.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply